An important biologic for the treatment of atopic dermatitis is dupilumab, an IL-4 receptor-α inhibitor that blocks both IL-4 and IL-13 activity and is approved for the treatment of moderate-to-severe atopic dermatitis in patients 6 years of age and older (for review see [254]). Here, IL4 is linked to atopic eczema.